Islet graft primary nonfunction and its prevention.
Arita
S
S
UCLA-VA Islet Transplant Program, Department of Surgery, UCLA School of Medicine and VAMC/WLA, Los Angeles, California 90073, USA.
Smith
C V
CV
Nagai
T
T
Sakamoto
Y
Y
Maruyama
M
M
Mullen
Y
Y
D000818:Animals; D000831:Animals, Newborn; D000975:Antioxidants / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002839:Chromans / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000601:surgery*; D005951:Glucose Tolerance Test; D006085:Graft Survival / Q000187:drug effects; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007249:Inflammation / Q000517:prevention & control; D016381:Islets of Langerhans Transplantation / Q000473:pathology / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D017035:Pravastatin / Q000627:therapeutic use*; D013370:Subrenal Capsule Assay; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic
D000975:Antioxidants; D001786:Blood Glucose; D002839:Chromans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin; C010643:6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid